Pharmacokinetic Studies and Services (PK Studies)

Pharmacokinetic studies (PK Studies) are key activities of early drug development. Our Pharmacokinetic services (PK services) can be exploratory, or can be more extensive. Understanding the pharmacokinetic properties (PK) of a test article is an essential component of drug discovery and development programs. GVK BIO conducts regular PK studies and can also customize it based the requirements of the clients.

Pharmacokinetic PK Studies and toxicokinetic analyses are key activities of early drug development. Thoroughly understanding the DMPK of a potential clinical candidate can have a huge impact on the success of a drug discovery program.

PK and TK studies provide useful and required information that informs no effect levels (NOEL), human equivalent doses (HED), and pharmacokinetic/pharmacodynamic (PK/PD) drivers.  Carrying out PK studies enables the determination of PK parameters such as AUC, clearance, volume of distribution, half-life, Cmax, and Cmin.

Rapid PK Screening

The iterative nature of in vivo PK screening requires rapid cycle times with changing priorities. We have built a team of experienced scientists with facilities and processes designed specifically to meet these challenging requirements.

From standard screening to more complex studies, our team of experienced team can also assist in designing the best strategy and protocols customized to suit any drug discovery program. Rapid study initiations facilitated by our maintenance supply of rodents and colonies of non-rodent species along with standardized protocols and fully integrated LC-MS/MS bioanalysis of PK samples, including small volume samples, result in better data faster

GVK BIO ensures safe and efficacious dosage regimens through the application of pharmacokinetic / pharmacodynamic principles and the determination of drug serum concentrations. The iterative nature of in vivo PK services requires rapid cycle times with changing priorities. We have built a team of experienced scientists with facilities and processes designed specifically to meet these challenging requirements.

Our Pharmacokinetic Services team conducts typical pharmacokinetic study which involves administering a fixed amount of the drug (the dose) to the subject (various animals) and at various times post dose, samples of an easily accessible tissue (usually blood/plasma) are drawn and collected for analysis of the drug

From standard screening to more complex PK studies, our team of experienced study directors can also assist in designing the best strategy and protocols customized to suit any drug discovery program.

In Vivo PK Studies
  • Rank-ordering compounds/formulations
  • Bioavailability and bioequivalence
  • Dose proportionality (ascending dose)
  • Dose linearity (multiple dose)
  • Drug-drug interactions
  • Special populations
  • Tissue distribution (non-radioactive and radioactive)
  • Blood brain barrier
  • Toxicokinetics
  • Anti-drug antibodies
  • Non-compartmental and compartmental pharmacokinetics
  • Pharmacodynamic and pharmacokinetic/pharmacodynamics modeling
  • Input into study design, including preclinical-to-clinical considerations (allometric scaling and human equivalent dose projections)
Administration Routes and Collection
  • Single agents, cassette dosing, single dose and repeat dose
  • Dosing by PO, IV, IP, SC, etc.
  • Serial sampling in all species
  • Microsampling
  • Tissue, urine and CSF collection
  • Bile collections by bile duct cannulation (BDC)
  • Fully integrated bioanalysis services
Surgical Models
  • Bile duct cannulation
  • Vascular access ports
  • Portal vein cannulation
  • Intestinal access ports

Pharmacokinetic Studies and Services will include: 

  • Evaluating compounds in various formulations, both solution as well as suspension dosing in various species.
  • Studying correlative aspects between the in vitro and in vivo metabolism of analogs to increase throughput and help lower cost.
  • Dose escalation studies in rats or dogs with the potential for follow up in the 7- and 28-day tox studies in rats/dogs that would help plan for Phase I and in some cases Phase II clinical trials.
  • Cassette (n-in-1) PK for early discovery compound screening and decision prioritization
  • Drug distribution in tissue/organ and body fluid and determination of blood and brain ratio for brain penetration
  • Metabolic kinetics with active metabolites

In order to provide a significant enhancement in speed and efficiency it becomes highly beneficial at GVK BIO to conduct both the in vivo PK quantification and identification of the major metabolites on a single instrument platform. provides our customers fast turnaround and close management of PK screening projects.

That was the comprehensive list of our Pharmacokinetic Services. Feel free to contact us regarding any query. Our PK Services team will get in touch with you as soon as possible.

© 2017 | GVK Biosciences Private Limited, All Rights Reserved | Terms & Conditions

Log in with your credentials

Forgot your details?